Cannabis Science Inc. Announces Initiation of GMP Development Plan for CS-TATI-1

Published: Aug 13, 2012

COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Cannabis Science (CBIS), a pioneering U.S. Biotech Company developing pharmaceutical to meet global public health challenges is pleased to announce the initiation of GMP development plan for CS-TATI-1 with the initial production of CS-TATI-1 to be performed in Colorado under C-GMP conditions evaluated by the FDA for initial human studies to treat HIV associated Kaposi Sarcoma.

Back to news